NCT02988960 2026-01-09
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
Clinical Trials
17 trialsNCT05599984 2025-10-20
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT05822752 2025-08-14
LIVIGNO-1
AbbVie
Phase 2 Active not recruiting
NCT03893955 2025-08-12
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT06632951 2025-08-11
LIVIGNO-3
AbbVie
Phase 2 Active not recruiting
NCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT03821935 2025-05-25
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT04807972 2025-01-07
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
AbbVie
Phase 1 Terminated
NCT06119217 2024-12-04
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
Phase 2 Active not recruiting
NCT03639194 2024-02-09
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
AbbVie
Phase 1 Completed
NCT01946074 2023-12-15
A Study of ABT-165 in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT04196283 2023-02-27
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
AbbVie
Phase 1 Completed
NCT03071757 2022-04-28
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
Phase 1 Completed
NCT03000257 2022-04-14
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT03818542 2020-12-31
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
AbbVie
Phase 1 Terminated
NCT03035279 2020-02-20
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
AbbVie
Phase 1 Terminated
NCT03138408 2019-05-14
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
AbbVie
Phase 1 Terminated